The Medicines Company recent said it will be presenting data on its antimicrobial products and late-state product candidates at the 27th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017) on April 22-25 in Vienna, Austria.
The Centers for Medicare and Medicaid Services (CMS) Office of Minority Health recently released two reports on Medicare Advantage enrollees’ quality of care, one on the difference between men and women and one on the differences between racial and ethnic groups.
New research from Boston Healthcare Associates on biologic therapies for rheumatoid arthritis (RA) suggests that those therapies have benefits for patients who exceed their value as understood when they were initially approved.
The American Cancer Society Cancer Action Network (ACS CAN) recently criticized a new rule from the Centers for Medicare and Medicaid Services (CMS) that will restrict access to special enrollment periods and reduce requirements for Essential Community Providers.
Takeda Pharmaceutical Company Limited and Ultragenyx Pharmaceutical Inc., a company that develops products for rare and ultra-rare diseases, recently announced a strategic partnership for developing and commercializing therapies.
Takeda Pharmaceutical Company Limited and Theravance Biopharma Inc. recently entered a global license, development and commercialization agreement for TD-8954, a potential treatment for gastrointestinal motility disorders like enteral feeding intolerance (EFI).
The Medicines Company recently completed enrollment for the second phase of its study on PCSK9si, which the company is seeking to show can reduce LDL-C, or ‘bad cholesterol,’ with just a single-dose treatment every six months.
The Michael J. Fox Foundation (MJFF) plans to partner with Georgetown University to offer a fellowship that will train students in the Georgetown Program for Regulatory Science and Medicine to optimize clinical trial designs and better support novel therapies.
The American Heart Association recently signed a memorandum of understanding (MOU) with the Chinese Medical Association’s Chinese Society of Cardiology, which will see the institutions cooperate on establishing measures to improve the system of care for heart attack patients in China.
National Cancer Institute initiative Genomic Data Commons recently launched at its operations center in the University of Chicago, from which it hopes to provide researchers with genomic and clinical data.
New research published in the American Heart Association’s 'Hypertension' journal suggests that insufficient sleep as well as sleep-cycle disruption -- typical of shift workers and chronically sleep-deprived people -- may lead to increased risks for cardiovascular disease.
The ACS CAN recently supported a fiscal year 2016 spending bill markup from the Senate Appropriations Subcommittees on Labor, Health and Human Services and Education, which includes increases in cancer research spending.
A briefing, hosted by the Healthcare Leadership Council and sponsored by Takeda Pharmaceuticals USA Inc.-Lundbeck LLC and New York-Presbyterian Hospital, recently examined the costs associated with depression and the impact cognitive disorders pose to patients’ ability to function.
The American Diabetes Association recently honored Nicolaas Schaper with the 2016 Roger Pecoraro Award, in recognition of his research efforts on diabetic foot complications, at its 76th Scientific Sessions in New Orleans, Louisiana.
Elizabeth Walker recently accepted the 2016 Richard R. Rubin Award from the American Diabetes Association in recognition of her work, which is focused on studying and understanding the behavioral aspects of diabetes in diverse populations.
A report released this week by the Congressional Budget Office (CBO) shows that congressional efforts to control spending on Medicare have not significantly impacted the problem, leading to calls for more sweeping changes from some legislators.
Bristol-Myers Squibb Company recently announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of a combination Opdivo and Yervoy treatment for patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.